DiaSorin S.p.A. Analysis (March 2026) | Price Development & Price Target

DiaSorin S.p.A.

BIT:DIA

€ 58,26

€-0,96 (-1,62%)

58,26 €

€-0,96 (-1,62%)

End-of-day quote: 03/27/2026

DiaSorin S.p.A. Stock Value

The analyst rating for BIT:DIA is currently Outperform.

Outperform

DiaSorin S.p.A. Company Info

EPS Growth 5Y

5,17%

Market Cap

€3,14 B

Long-Term Debt

€0,75 B

Quarterly earnings

05/06/2026 (E)

Dividend

€1,28

Dividend Yield

2,20%

Founded

1968

Industry

Health Care

Country

Italy

Website

DiaSorin S.p.A.

ISIN Number

IT0003492391

Website

http://int.diasorin.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

€75,00

28.73%

Last Update: 03/28/2026

Analysts: 12

Highest Price Target €95,00

Average Price Target €75,00

Lowest Price Target €58,00

In the last five quarters, DiaSorin S.p.A.’s Price Target has fallen from €155,62 to €109,71 - a -29,50% decrease. Five analysts predict that DiaSorin S.p.A.’s share price will increase in the coming year, reaching €75,00. This would represent an increase of 28,73%.

Top growth stocks in the health care sector (5Y.)

What does DiaSorin S.p.A. do?

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits. Business Segments The company operates through Immunodiagnostics, Molecular Diagnostics, and Licensed Technologies segments. Immunodiagnostics This segment operates with a comprehensive array of assays primarily focused on areas, such as infectious diseases, hormonal disorders, and autoimmune diseases. The company's products in this segment are instrumental in de...

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits.

Business Segments

The company operates through Immunodiagnostics, Molecular Diagnostics, and Licensed Technologies segments.

Immunodiagnostics

This segment operates with a comprehensive array of assays primarily focused on areas, such as infectious diseases, hormonal disorders, and autoimmune diseases. The company's products in this segment are instrumental in delivering quick and accurate results, supporting healthcare professionals' decision-making processes. The company has developed advanced platforms capable of independent customization of tests, which enhances laboratory efficiency and adaptability.

Molecular Diagnostics

This segment encompasses a suite of products for detecting genetic materials and pathogens. These products are particularly critical in identifying infectious diseases through advanced technologies, such as PCR (Polymerase Chain Reaction). This segment is noteworthy for its flexibility, enabling clinical laboratories to conduct a wide variety of tests while keeping pace with emerging public health needs.

Licensed Technologies

This segment represents a strategic segment for the company, which involves partnerships and agreements allowing third parties to utilize its proprietary technologies. These agreements not only enhance revenue streams but also extend the company's footprint in the healthcare market.

Business Strategy

The company's business strategy is focused on innovation, international expansion, and the cultivation of strategic partnerships. The company seeks to maintain a leading role in the global diagnostic industry by investing significantly in research and development. This focus ensures that new products not only meet the existing standards but also anticipate future market demands.

Moreover, the company emphasizes the importance of geographic diversification as a vital component of its strategy. By exploring untapped markets and reinforcing its presence in established ones, the company strives to build a robust global brand renowned for reliability and innovation. Through these efforts, the company seeks to achieve long-term sustainable growth while addressing the diverse needs of different healthcare systems around the world.

Additionally, the cultivation of alliances with key players in biotechnology and pharmaceuticals further enhances the company's product development capabilities and accelerates time-to-market for new diagnostic solutions. The company seeks to promote collaborative innovation so that it can respond to challenges in healthcare more effectively, particularly in areas, such as infectious disease management and chronic conditions.

Products and Services

The company's product portfolio is extensive and is continually evolving to incorporate cutting-edge technologies. The company offers a wide range of immunodiagnostic assays, which are designed to measure antibodies and hormones, and are critical in various disease diagnostics. These assays cover clinical areas, including infectious diseases, oncology, and endocrine disorders.

In molecular diagnostics, the company delivers innovative platforms capable of performing PCR-based tests that detect diseases through genetic markers. This segment has seen significant growth, particularly in the context of rapidly evolving healthcare needs amidst global health crises.

The company provides a series of licensed technologies, which enable external partners to utilize the company's distinct methodologies and systems to produce and market their own diagnostic solutions.

The integration of unique software applications for data analysis and laboratory management systems further enhances the company's offerings, allowing clients to make informed decisions based on real-time data and insights.

Geographical Markets

The company serves established and emerging markets worldwide, with a strong presence in Europe, North America, and the Asia-Pacific region. The company continuously seeks to enhance its geographic reach through strategic initiatives.

Sale of Segment

The company divested its Flow Cytometry & Imaging business unit in February 2023, enabling a sharper focus on its core segments of Immunodiagnostics and Molecular Diagnostics.

Seasonality

The diagnostic industry often experiences variations in sales patterns due to seasonality, which can significantly influence demand for certain products. In general, the company's sales exhibit peaks during certain periods of the year, especially during seasonal outbreaks of diseases that increase the need for diagnostic testing. As such, the company closely monitors market trends and adjusts its operational strategies in anticipation of seasonal demands.

Customers

The company serves a broad spectrum of customers, including hospitals, clinical laboratories, and diagnostic networks. The customer base encompasses thousands of healthcare institutions across numerous countries, enabling the company to cater to a diverse range of diagnostic needs. The ability to provide customized solutions facilitates the development of long-term relationships with clients who require reliable diagnostic tools.

Sales and Marketing

The company employs a multi-faceted marketing and distribution strategy that includes direct sales, distribution partnerships, and online platforms to reach its customers effectively. The emphasis on establishing strong relationships with distributors empowers the company to extend its geographical presence efficiently. Direct sales teams are operated within key markets to ensure client engagement, product training, and support.

History

DiaSorin S.p.A. was founded in 1968.

DiaSorin S.p.A. Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Revenue distribution by sectors:** - Immunodiagnostics: approx. 60% - Molecular diagnostics: approx. 40% **TOP 3 markets:** 1. **USA:** approx. 45% 2. **Europe:** approx. 35% 3. **Asia-Pacific:** approx. 15% DiaSorin S.p.A. generates the majority of its revenue from immunodiagnostics, followed b...

At which locations are the company’s products manufactured?

**Production sites of DiaSorin S.p.A.:** 1. **Italy** - Headquarters and significant production facility. 2. **USA** - Several production plants, especially in Stillwater, Minnesota. 3. **Germany** - Production site for specific diagnostic products. 4. **China** - Production and distribution sites...

What strategy does DiaSorin S.p.A. pursue for future growth?

**Revenue Growth:** Estimated 10% annually (2025) **Focus on Innovation:** DiaSorin S.p.A. strongly emphasizes the development of new diagnostic tests and technologies to strengthen its market position. This includes expanding the existing product portfolio as well as introducing innovative solutio...

Which raw materials are imported and from which countries?

**Main raw materials:** Biochemical reagents, plastic components, electronic components **Main importing countries:** USA, China, Germany DiaSorin S.p.A. is a company specializing in the development and manufacturing of diagnostic tests. The production of these tests requires a variety of raw mate...

How strong is the company’s competitive advantage?

**Market Share:** Estimated at 10% in the global diagnostics market (2025) **Research and Development Ratio:** 7% of revenue (2024) **Gross Margin:** 67% (2024) DiaSorin S.p.A. has a significant competitive advantage in the diagnostics market, supported by several factors. The market share of a...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** approximately 45% (2025, estimated) **Insider Purchases/Sales:** No significant transactions reported (2025, estimated) The institutional investor share in DiaSorin S.p.A. is estimated to be around 45%, based on historical data and typical industry ratios. These...

What percentage market share does DiaSorin S.p.A. have?

**Market share of DiaSorin S.p.A.:** Estimated around 10% (2025) **Major competitors and their market shares:** 1. **Roche Diagnostics:** 20% 2. **Abbott Laboratories:** 18% 3. **Siemens Healthineers:** 15% 4. **Thermo Fisher Scientific:** 12% 5. **DiaSorin S.p.A.:** 10% 6. **Bio-Rad Laboratories:*...

Is DiaSorin S.p.A. stock currently a good investment?

**Revenue Growth:** 8.5% (2024) **EBITDA Margin:** 35% (2024) **Research and Development Ratio:** 12% of revenue (2024) DiaSorin S.p.A. achieved a revenue growth of 8.5% in 2024, attributed to strong demand for its diagnostic products and successful market expansion. The EBITDA margin of 35% demons...

Does DiaSorin S.p.A. pay a dividend – and how reliable is the payout?

**Dividend yield:** 1.5% (estimated for 2025) **Dividend history:** Steady payout in recent years DiaSorin S.p.A. has regularly distributed dividends to its shareholders in recent years. The dividend yield for the year 2025 is estimated to be around 1.5%, based on past payouts and current market...

New support ticket

Explore

DiaSorin S.p.A. Stock Value

DiaSorin S.p.A. Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does DiaSorin S.p.A. do?

DiaSorin S.p.A. Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

DiaSorin S.p.A. Stock Value

DiaSorin S.p.A. Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does DiaSorin S.p.A. do?

DiaSorin S.p.A. Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.